Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Raises EPS, Revenue Guidance as Phadia Purchase Closes

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today raised its adjusted EPS and revenues guidance for full-year 2011 following the completion of its purchase of specialty diagnostics firm Phadia.

Thermo Fisher announced that its $3.5 billion purchase of the firm had closed and said that the acquisition is expected to contribute $.07 to full-year EPS, a $.01 increase from an original estimate of $.06, excluding restructuring, amortization of acquisition-related intangible assets, and other gains and costs.

As a result, it raised adjusted EPS guidance to a new range of between $4.15 and $4.25, which would represent a 20 percent to 23 percent increase over 2010 EPS. During its recent second-quarter earnings release, Thermo Fisher had given adjusted EPS guidance of between $4.08 and $4.18.

Phadia is also expected to contribute $190 million in revenues to Thermo Fisher for the year, and as a result the company raised its revenue guidance to a new range of $11.79 billion to $11.89 billion, which would represent around 12 percent growth over 2010.

Thermo Fisher had given guidance of between $11.60 billion to $11.70 billion last month.

Based in Uppsala, Sweden, Phadia has 1,500 employees worldwide and generated €367 ($529.5 million) in revenues in 2010. Phadia will become part of Thermo Fisher's Specialty Diagnostics business.

Following Thermo Fisher's announcement, Jon Wood of investment bank Jefferies raised his full-year 2011 EPS and revenue estimates for the company to $4.22 and $11.9 billion, respectively. He previously had estimated EPS of $4.15 on revenues of $11.7 billion.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.